Canada · Delayed Price · Currency is CAD MediPharm Labs Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw positive adjusted EBITDA and strong gross margins despite lower revenue, with disciplined execution and international expansion driving performance. The company remains well-capitalized, focused on regulated medical markets, and is mitigating Canadian reimbursement headwinds.
Fiscal Year 2025
-
Full-year revenue grew 8% to CAD 45 million, led by a 42% increase in international medical cannabis, now over half of total revenue. Gross margin improved to 31%, and net loss narrowed to CAD 8.3 million. Strong balance sheet, no material debt, and continued focus on international growth.
-
Q3 2025 saw 17% revenue growth year-over-year, led by an 83% increase in international medical cannabis sales, now 56% of total revenue. Gross margin declined to 22% due to product mix and plant shutdowns, but management expects improvement as new higher-margin products and markets ramp up.
-
Q2 2025 saw 14% revenue growth year-over-year, led by a 50% surge in international medical cannabis sales, now 57% of total revenue. Gross margin was 28%, with adjusted EBITDA at -$0.6 million. The company remains debt-free, cash-rich, and focused on global expansion and innovation.
-
Q1 2025 saw record gross margin, positive adjusted EBITDA, and 87% growth in international medical cannabis revenue, now over half of total sales. Strong cash position, facility ownership, and strategic execution support continued expansion, despite activist shareholder challenges.
Fiscal Year 2024
-
Q2 2024 saw near breakeven Adjusted EBITDA and record revenue, driven by strong international sales and cost reductions. Gross margin and cash position improved, with further growth expected from new products and international expansion.